Published in J Clin Oncol on October 01, 1993
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol (2010) 1.25
Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs (2005) 1.13
Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. PLoS One (2012) 1.00
Immunotherapy of distant metastatic disease. Ann Oncol (2009) 0.96
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer (1998) 0.94
Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes (2012) 0.92
Single-agent interleukin-2 in the treatment of metastatic melanoma. Curr Oncol (2007) 0.85
Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs (2002) 0.84
Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. Oncologist (2012) 0.83
Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. Cancer Immunol Immunother (2014) 0.83
Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. J Oncol (2010) 0.82
Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag (2016) 0.81
Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2). PLoS One (2014) 0.79
In vitro assessment of choline dihydrogen phosphate (CDHP) as a vehicle for recombinant human interleukin-2 (rhIL-2). Cell Mol Bioeng (2012) 0.79
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma. Br J Cancer (1996) 0.78
Platelet-cytokine Complex Suppresses Tumour Growth by Exploiting Intratumoural Thrombin-dependent Platelet Aggregation. Sci Rep (2016) 0.77
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma. Br J Cancer (1995) 0.77
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). Invest New Drugs (2004) 0.76
Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice. Virus Genes (2016) 0.75
A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma. Invest New Drugs (2002) 0.75
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med (1998) 5.74
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 4.73
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med (1990) 3.88
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood (1994) 3.74
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol (1998) 3.64
Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. J Clin Oncol (1990) 3.14
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 2.66
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol (2001) 2.47
Are intravenous fluids morally required for a dying patient? Arch Intern Med (1983) 2.40
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood (2001) 2.40
Extramedullary acute promyelocytic leukemia. Cancer (1996) 2.31
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol (1995) 2.26
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol (2008) 2.23
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs (1992) 2.22
Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood (2001) 2.20
Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol (2001) 2.12
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol (1998) 1.91
An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med (1990) 1.89
Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. Cancer (1991) 1.77
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol (1993) 1.76
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol (1994) 1.76
Phase I clinical and pharmacokinetic study of taxol. Cancer Res (1987) 1.74
Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline. Chest (1991) 1.72
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol (1999) 1.71
Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med (1982) 1.67
CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol (1993) 1.63
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer (2013) 1.57
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol (1988) 1.56
Nosocomial sepsis associated with interleukin-2. Ann Intern Med (1990) 1.56
Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol (1996) 1.52
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med (1978) 1.52
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol (1998) 1.51
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol (1990) 1.49
Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. J Clin Oncol (1998) 1.48
Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med (1988) 1.46
Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am (1997) 1.45
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol (1987) 1.44
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol (1996) 1.41
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst (1991) 1.40
The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J Sci Am (1998) 1.40
Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in diffuse large-cell lymphoma. Leuk Lymphoma (1998) 1.39
Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group. Cancer (1997) 1.38
Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res (2000) 1.38
The human T-cell leukemia-lymphoma virus in the southeastern United States. JAMA (1983) 1.34
Cytoreductive surgery for stage IV renal cell carcinoma. J Urol (1995) 1.33
Taxol produces a predominantly sensory neuropathy. Neurology (1989) 1.32
Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med (1979) 1.28
Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia (1999) 1.26
Oestrogen receptors in human malignant melanoma. Lancet (1976) 1.26
Association of the human type C retrovirus with a subset of adult T-cell cancers. Cancer Res (1983) 1.25
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med (1983) 1.23
Rapid migration of 111indium-labeled granulocytes to sites of infection. N Engl J Med (1981) 1.22
The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med (1988) 1.21
Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol (1983) 1.21
Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol (1993) 1.20
Aggressive treatment for postcardiac transplant lymphoproliferation. Blood (1995) 1.20
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol (1995) 1.20
Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res (1999) 1.20
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol (1989) 1.19
Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol (2005) 1.17
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol (1990) 1.17
Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol (1987) 1.17
Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol (2001) 1.16
Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells. J Immunol (1989) 1.15
High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am (1997) 1.15
Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol (2001) 1.14
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol (1993) 1.14
Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy. Am J Med (1979) 1.13
Diffuse histiocytic lymphoma involving the gastrointestinal tract. Cancer (1978) 1.13
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood (1998) 1.13
Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. J Clin Oncol (1998) 1.12